Pharmacopsychiatry 2000; 33(4): 153-154
DOI: 10.1055/s-2000-11227
Case Report
© Georg Thieme Verlag Stuttgart · New York

Is Clozapine Useful in Schizophrenic Patients with Concomitant Chronic Inflammatory Disease?

A. Schreiner, W. Hewer
  • From the Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
Further Information

Publication History

09.06.1999

17.01.2000

Publication Date:
31 December 2000 (online)

Introduction

In terms of side effects affecting the hematological system, clozapine is best known for its propensity to cause severe leukopenia and agranulocytosis [1]. Hematological dysfunction in the course of clozapine treatment can be either a direct effect of the drug or a sign of various medical disorders unrelated to clozapine. Leukocytosis, for instance, can be either a side effect of clozapine or an indicator for a concomitant infection. Leukopenia, on the other hand, may be found as a harmless, often transient phenomenon, as well as an early sign of incipient agranulocytosis. Effects of other drugs used concurrently with clozapine and the possibility of laboratory errors should also be considered. Previous studies have differentiated between transient “benign” neutropenia, recurrent transient neutropenia, and progressive neutropenia [2] [3] [4].Transient neutropenia is a disorder in which neutrophil granulocytes drop below a defined value, but return to normal values with continued clozapine treatment. Plasma levels of clozapine do not correlate to any of the hematological disorders described above [5]. However, a recent report suggested that N-desmethylclozapine, the major metabolite of clozapine, is associated with bone marrow toxicity comparable to carbamazepine [6].

References

  • 1 Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.  BJP. 1996;  169 483-488
  • 2 Hummer M, Kurz M, Barnas C, Fleischhacker W W. Transient neutropenia induced by clozapine.  Psychopharm. Bull.. 1992;  28 287-290
  • 3 Veys P A, Wilkes S, Shah S, Noyelle R, Hoffbrand A V. Clinical experience of clozapine-induced neutropenia in the UK. Laboratory investigation using liquid culture systems and immunofluorocytometry.  Drug Safety. 1992;  7 Suppl. 1 26-32
  • 4 Lindstrom L H. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years.  Acta Psych. Scand.. 1988;  77 524-529
  • 5 Centorrino F, Baldessarini R J, Flood J G, Kando J C, Frankenburg F R. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites.  AJP. 1995;  152 610-612
  • 6 Gerson S L, Arce C, Meltzer H Y. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis.  B. J. Haematol.. 1994;  86 555-561
  • 7 Emilia G, Luppi M, Ferrari M G, Barozzi P, Marasca R, Torelli G. Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis.  J. Med. Virology. 1997;  53 182-184
  • 8 Pirmohamed M, Park B K. Mechanisms of clozapine-induced agranulocytosis.  CNS drugs. 1997;  7 139-158
  • 9 Ahokas A, Elonen E. Circadian rhythm of white blood cells during clozapine treatment.  Psychopharmacology. 1999;  144 301-302

Dr. Andreas Schreiner

c/o Department of Psychiatry and Psychotherapy Central Institute of Mental Health

P.O. Box 12 21 20

68072 Mannheim

Germany

Phone: ++49 2137 955153

Fax: ++49 2137 955672

Email: ASchrein@Jacde.JNJ.com

    >